Dr. Leukam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-7000Fax+1 844-579-7610
Summary
- I am a hematology/oncology fellow specializing in lymphoma and cellular therapeutics. I use bioinformatic techniques to study the interaction of the immune system with changes in tumor genes and gene expression. I also design clinical trials that take advantage of specific changes in tumor genes.
My background includes wet-lab experience in molecular biology and genetics, database analysis and computational biology. I am currently obtaining a MSc in biomedical informatics to develop skills in computational research and clinical informatics.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2017- University of ChicagoResidency, Hematology and Medical Oncology, 2014 - 2020
Loyola University Chicago Stritch School of MedicineClass of 2014
University of Notre DameBA, Psychology, 2002 - 2006
Certifications & Licensure
MA State Medical License 2020 - 2025
IL State Medical License 2017 - 2020
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
AHAACLS
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha, 2013
Publications & Presentations
PubMed
- CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.Emil Arjun Kumar, Koorosh Korfi, Findlay Bewicke-Copley, Karina Close, James Heward
British Journal of Haematology. 2024-11-01 - 12 citationsRefining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma.Kirk E. Cahill, Michael J. Leukam, Peter A. Riedell
Leukemia & Lymphoma. 2020-03-20 - 89 citationsPD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.James Godfrey, Sravya Tumuluru, Riyue Bao, Michael J. Leukam, Girish Venkataraman
Blood. 2019-05-23
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
